Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge

被引:156
作者
Johnson, TR
Johnson, JE
Roberts, SR
Wertz, GW
Parker, RA
Graham, BS
机构
[1] Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA
[4] Auburn Univ, Dept Bot & Microbiol, Auburn, AL 36849 USA
[5] Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA
[6] Harvard Univ, Sch Med, Dept Med Biostat, Boston, MA USA
关键词
D O I
10.1128/JVI.72.4.2871-2880.1998
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The respiratory syncytial virus (RSV) G glycoprotein promotes differentiation of type 2 CD4(+) T lymphocytes and induces an eosinophilic response in lungs of RSV-infected mice. A unique feature of G is that a second initiation codon in the transmembrane region of the glycoprotein results in secretion of soluble protein from infected cells. Recombinant vaccinia viruses that express wild-type G (vvWT G), only secreted G (vvM48), or only membrane-anchored G (vvM48I) were used to define the influence of G priming on immunopathogenesis. Mice immunized with vvM48 had more severe illness following RSV challenge than did mice primed with vvWT G or vvM48I. Coadministration of purified G during priming with the construct expressing membrane-anchored G shifted immune responses following RSV challenge to a more Th2-like response. This was characterized by increased interleukin-5 in lung supernatants and an increase in G-specific immunoglobulin G1 antibodies. Eosinophils were present in the infiltrate of all mice primed with G-containing vectors but were greatest in mice primed with regimens including secreted G. These data suggest the form of G protein available for initial antigen processing and presentation is an important factor in promoting Th2-like immune responses, including the induction of lung eosinophilia. The ability of RSV to secrete G protein may therefore represent a viral strategy for immunomodulation and be a key determinant of disease pathogenesis.
引用
收藏
页码:2871 / 2880
页数:10
相关论文
共 69 条
  • [1] DISTINCT PATTERNS OF T-CELL AND B-CELL IMMUNITY TO RESPIRATORY SYNCYTIAL VIRUS-INDUCED BY INDIVIDUAL VIRAL-PROTEINS
    ALWAN, WH
    OPENSHAW, PJM
    [J]. VACCINE, 1993, 11 (04) : 431 - 437
  • [2] DISTINCT TYPES OF LUNG-DISEASE CAUSED BY FUNCTIONAL SUBSETS OF ANTIVIRAL T-CELLS
    ALWAN, WH
    KOZLOWSKA, WJ
    OPENSHAW, PJM
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (01) : 81 - 89
  • [3] ALWAN WH, 1992, CLIN EXP IMMUNOL, V88, P527
  • [4] ALWAN WH, 1993, J IMMUNOL, V150, P5211
  • [5] PROTECTIVE AND DISEASE-ENHANCING IMMUNE-RESPONSES TO RESPIRATORY SYNCYTIAL VIRUS
    ANDERSON, LJ
    HEILMAN, CA
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (01) : 1 - 7
  • [6] EXPRESSION OF THE MAJOR GLYCOPROTEIN-G OF HUMAN RESPIRATORY SYNCYTIAL VIRUS FROM RECOMBINANT VACCINIA VIRUS VECTORS
    BALL, LA
    YOUNG, KKY
    ANDERSON, K
    COLLINS, PL
    WERTZ, GW
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (02) : 246 - 250
  • [7] BANGHAM CRM, 1986, J IMMUNOL, V137, P3973
  • [8] CYTO-TOXIC T-CELL RESPONSE TO RESPIRATORY SYNCYTIAL VIRUS IN MICE
    BANGHAM, CRM
    CANNON, MJ
    KARZON, DT
    ASKONAS, BA
    [J]. JOURNAL OF VIROLOGY, 1985, 56 (01) : 55 - 59
  • [9] VACCINIA VIRUS EXPRESSION VECTOR - COEXPRESSION OF BETA-GALACTOSIDASE PROVIDES VISUAL SCREENING OF RECOMBINANT VIRUS PLAQUES
    CHAKRABARTI, S
    BRECHLING, K
    MOSS, B
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1985, 5 (12) : 3403 - 3409
  • [10] COTTON RATS PREVIOUSLY IMMUNIZED WITH A CHIMERIC RSV FG GLYCOPROTEIN DEVELOP ENHANCED PULMONARY PATHOLOGY WHEN INFECTED WITH RSV, A PHENOMENON NOT ENCOUNTERED FOLLOWING IMMUNIZATION WITH VACCINIA RSV RECOMBINANTS OR RSV
    CONNORS, M
    COLLINS, PL
    FIRESTONE, CY
    SOTNIKOV, AV
    WAITZE, A
    DAVIS, AR
    HUNG, PP
    CHANOCK, RM
    MURPHY, BR
    [J]. VACCINE, 1992, 10 (07) : 475 - 484